News | Cath Lab | January 23, 2017

New Report Highlights National Trends in Heart Disease Treatments

Data show registries are advancing effectiveness and safety of patient care

NCDR, ACC, JACC, American College of Cardiology, national trends, heart disease treatments, trends in cardiovascular care

January 23, 2017 — Over 93 percent of heart attack patients are receiving stents within the guideline-recommended threshold of 90 minutes after arriving at the hospital, with the median time to stenting only 59 minutes, according to new data. The data are part of a broad report on trends in heart disease care from the American College of Cardiology’s National Cardiovascular Data Registry, published in the Journal of the American College of Cardiology.

The report “Trends in Cardiovascular Care in the United States: a Report from Four American College of Cardiology National Cardiovascular Data Registry Programs,” provides insights into the patient populations, participating centers and patterns of care based on 2014 data from four of the 10 NCDR programs — CathPCI Registry, ICD Registry, ACTION Registry-GWTG and IMPACT Registry. 

The authors of the report said the registry data provide unique perspectives into the care and outcomes of heart disease care in the United States and illustrate the strength of national quality programs, like NCDR, in advancing the effectiveness and safety of treatments for heart disease patients.

“We were able to report on the care and outcomes of patients undergoing common cardiovascular procedures, including percutaneous coronary interventions, implantable defibrillators and interventions for congenital heart disease, as well as for patients with acute heart attacks,” NCDR Management Board Chair and lead author of the study Frederick A. Masoudi, M.D., MSPH, FACC, said. “In some cases, hospitals are consistently providing excellent care; the registries, however, allow us to identify those aspects of care where the cardiovascular clinical community can improve.”

Key findings from each registry include:

CathPCI Registry

  • Of the 667,424 patients undergoing PCI in 2014, 35.3 percent of PCIs were performed for elective indications, compared to 64.7 percent performed for non-elective indications;
  • Between 2011 and 2014, the use of femoral access decline from 88.4 percent to 74.5 percent, while the use of radial access increased from 10.9 percent to 25.2 percent;
  • Use of evidence-based therapies, including aspirin, P2Y12 inhibitors and statins for eligible patients, continue to remain high at 93.3 percent;
  • Median door-to-balloon time for primary PCI for ST-elevation myocardial infarction (STEMI) also remains strong at 59 minutes for patients receiving PCI at the presenting hospital and 105 minutes for transfer patients.

ICD Registry

  • Of the 158,649 patients receiving implantable cardioverter defibrillator (ICD) therapy in 2014, 120,228 received a device for primary prevention reasons, compared to 38,421 who received a device for secondary prevention indications;
  • Of all ICD implants in 2014, 25 percent involved single chamber devices, 32 percent involved dual chamber devices and 43 percent involved cardiac resynchronization therapy-defibrillator (CRT-D) devices, compared to 19 percent, 37 percent and 44 percent, respectively, in 2011; and
  • While use of evidence-based therapies are generally high, performance on a composite medication metric, including use of ACE or ARB for patients with left ventricular systolic dysfunction (LVSD) and beta blockers for patients with LVSD, could be a target for quality improvement efforts. Between 2011 and 2014 the composite rate of use grew from 76.7 percent to 80.3 percent, with room for continued improvement.

ACTION Registry-GWTG

  • Of the 182,903 patients with acute myocardial infarction (AMI) in 2014, 71,368 had STEMI, while 111,535 had non-ST-segment elevation acute coronary syndromes (NSTEMI);
  • There is room for improvement in the areas of overall defect-free care (78.4 percent); P2Y12 inhibitor use in eligible patients (56.7 percent); and use of aldosterone antagonists in patients with LV systolic dysfunction and either diabetes or heart failure (12.8 percent);
  • Compared to NSTEMI patients, STEMI patients were more likely to experience certain adverse events during hospitalization, including death (6.4 percent vs. 3.4 percent); cardiogenic shock (4.4 percent vs. 1.6 percent), or bleeding (8.5 percent vs. 5.5 percent); and
  • Of the STEMI patients, 95.8 percent underwent coronary angiography and 90.7 percent underwent PCI, compared to NSTEMI patients of which 81.9 percent underwent coronary angiography and 52.4 percent underwent PCI.

IMPACT Registry

  • Of the 20,169 patients with congenital heart disease undergoing cardiac catheterization or a catheter-based intervention, 86 percent were under the age of 18 and 24.6 percent were under one year old;
  • Procedures such as atrial septal defect (ASD) closure, patent ductus arteriosus (PDA) closure, aortic coarctation stenting and pulmonary valvulolasty had success rates exceeding 84 percent. Aortic coarctation balloon angioplasty was less successful at 55.1 percent; and
  • Device embolization was reported in 1.2 percent of ASD closure procedures and 1.1 percent of PDA closure procedures. A clinically significant increase in aortic regurgitation follow valvuloplasty was noted in 10.6 percent of cases.

In a corresponding executive summary also published in JACC, Masoudi said, “NCDR data provide a unique, clinically rich national perspective on the care and outcomes of high-impact cardiovascular conditions and procedures that are not available elsewhere.”

The full report can be read here.

For more information: www.jacc.org

 

Related NCDR CathPCI Registry articles:

• Radial Access, Same-Day Cardiac Procedure Could Save $300 Million Annually
• Better Prognosis for Some PCI Patients When Operators Perform More Procedures
• Study Finds Significant Variability in Doctors' Angioplasty Death Rates

 

Reference:

Masoudi, F.A., Ponirakis, A., de Lemos, J.A., Jollis, J.G., et al. "Trends in U.S. Cardiovascular Care: 2016 Report from 4 ACC National Cardiovascular Data Registries," JACC. Published online Dec. 23, 2016. DOI: https://doi.org/10.1016/j.jacc.2016.12.005

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init